Pre-exposure Prophylaxis

Active Resources: 34

Online and Self-Paced Learning

Fact Sheets

Patient Information

Coinfection Guidelines (Hep, TB, STIs)

Web Links

Articles: 4

  • U=U in PARTNER2 Study of MSM

    Susa Coffey's picture

    PARTNER1, whose results were reported last year,(1) was one of the studies that supported current efforts to promote the growing scientific consensus supporting "Treatment as Prevention" (TasP) or Undetectable = Untransmittable (U=U).

    PARTNER1 evaluated HIV...

  • HIV Meds Update: PrEP Uptake by Sex, Race, and Age

    Susa Coffey's picture

    At the ASM Microbe meeting in June, researchers from Gilead Sciences presented data on use of TDF/FTC (Truvada) PrEP in the United States according to sex and race. They evaluated national pharmacy databases to identify prescriptions of TDF/FTC given for PrEP between January 2012 and September...

  • PrEP: Bone Density Improves after Stopping TDF/FTC

    Susa Coffey's picture

    Tenofovir disoproxil fumarate (TDF) may cause decreases in bone mineral density (BMD) both in HIV-infected patients treated with TDF-containing ARV regimens and in HIV-uninfected persons who use it for PrEP. A substudy of the large iPrEx trial of TDF/FTC PrEP in MSM and transgender...

  • Tissue Levels of TAF: Too Low for PrEP?

    Susa Coffey's picture

    A pharmacokinetic study presented at the Conference on Retroviruses and Opportunistic Infections in Boston in February evaluated concentrations of tenofovir (TFV) and TFV-diphosphate (DP) in genital and rectal tissue and in anogenital fluid samples after administration of oral tenofovir...

Day Title
11/14
MidAtlantic AETC Webinar Wednesday Series
Event type: Webinars
11/15
National Rural Health Day
Event type: Awareness Days
11/20
Adherence Across the Life Span HIV Symposium
12/3
2018 Biomedical HIV Prevention Summit (The Summit)
Day Title
9/6
U.S. Conference on AIDS (USCA)
3/4
CROI 2018: Boston